Gianluigi Savarese
A5015344056- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- Potassium and Related Disorders
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Blood Pressure and Hypertension Studies
- Cardiac Arrhythmias and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac electrophysiology and arrhythmias
- Cardiac Structural Anomalies and Repair
- Lipoproteins and Cardiovascular Health
- Medication Adherence and Compliance
- Antiplatelet Therapy and Cardiovascular Diseases
- Metabolism, Diabetes, and Cancer
- Cardiac Valve Diseases and Treatments
- Erythropoietin and Anemia Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Mechanical Circulatory Support Devices
- Hormonal Regulation and Hypertension
- Pancreatic function and diabetes
- Cardiac Health and Mental Health
- Electrolyte and hormonal disorders
- Pharmaceutical Economics and Policy
Karolinska University Hospital
2016-2025
Karolinska Institutet
2016-2025
Stockholm South General Hospital
2024-2025
European Society of Cardiology
2023
Baylor College of Medicine
2023
Minneapolis Heart Institute Foundation
2021
University of Minnesota
2021
Massachusetts General Hospital
2019
Medical University of Vienna
2019
Boehringer Ingelheim (Germany)
2019
Heart failure (HF) is a global pandemic affecting at least 26 million people worldwide and increasing in prevalence. HF health expenditures are considerable will increase dramatically with an ageing population. Despite the significant advances therapies prevention, mortality morbidity still high quality of life poor. The prevalence, incidence, rates reported show geographic variations, depending on different aetiologies clinical characteristics observed among patients HF. In this review we...
65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic
Background— The pathogenic role of ischemic heart disease (IHD) in failure (HF) with reduced ejection fraction (HFrEF; EF <40%) is well established, but its and prognostic significance HF midrange (HFmrEF; 40%–50%) preserved (HFpEF; ≥50%) has been much less explored. Methods Results— We evaluated 42 987 patients from the Swedish Heart Failure Registry respect to baseline IHD, outcomes (IHD, HF, cardiovascular events, all-cause death), change during a median follow-up 2.2 years. Overall,...
The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects empagliflozin exercise patient-reported outcomes in heart failure (HF) reduced preserved ejection fraction (EF), without type 2 diabetes (T2D), reporting, for first time, sodium-glucose co-transporter-2 inhibition EF (HFpEF).HF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or (>40%, 315, EMPERIAL-Preserved), T2D, were randomized to 10 mg placebo 12 weeks....
Guidelines recommend early initiation of multiple guideline-directed medical therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and reduced ejection fraction. Understanding GDMT use is critical improving clinical practice.This study sought describe Japan, Sweden, the United States contemporary real-world settings.EVOLUTION HF (Utilization Dapagliflozin Other Guideline Directed Medical Therapies Heart Failure Patients: A Multinational Observational Study...
Use and dosing of guideline-directed medical therapy (GDMT) in patients with heart failure (HF) have been shown to be suboptimal. Among new users GDMT HF, we followed the real-life patterns dose titration discontinuation angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers, mineralocorticoid antagonists (MRA) receptor-neprilysin (ARNI).New were identified health care databases Sweden, UK US between 2016-2019. Inclusion criterion was a recent HF...
Abstract Iron deficiency (ID) is common in patients with cardiovascular disease. Up to 60% of coronary artery disease, and an even higher proportion those heart failure (HF) or pulmonary hypertension have ID; the evidence for cerebrovascular aortic stenosis atrial fibrillation less robust. The prevalence ID increases severity cardiac renal dysfunction probably more amongst women. Insufficient dietary iron, reduced iron absorption due hepcidin secondary low-grade inflammation associated...
Abstract Aim The management of cardiogenic shock remains a clinical challenge even in well‐developed healthcare systems, best illustrated by its high mortality despite numerous innovative proposals for management. aim this study was to describe temporal trends incidence, causes, use mechanical circulatory support, and Germany. Methods results Data on all patients treated German hospitals between 2005 2017 were obtained from the Federal Bureau Statistics. data set comprised 441 696 with...
Abstract Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be manifestation of various combinations cardiovascular, metabolic, pulmonary, renal, geriatric conditions. Thus, addition to treatment sodium–glucose cotransporter 2 inhibitors all patients, the most effective method improving outcomes therapy tailored each...